Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

NCT03409458 is registered in ClinicalTrials.gov with Promontory Therapeutics Inc. as lead sponsor.

NCT NCT03409458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03409458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Lead sponsor
Promontory Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 24, 2018
Completion date
August 31, 2022
Enrollment
68 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)